Skip to main content
TipRanks
Go Ultimate75% OFF

Skye Bioscience (SKYE) Stock Price & Analysis

1,005 Followers

SKYE Stock Chart & Stats

$1.03$0.03(3.00%)
At close: 4:00 PM EST
$1$1.5$2$2.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.98 - $1.05
52-Week Range
$0.50 - $11.04
Previous Close
$1.00
Volume
N/A
Average Volume (3M)
89.86K
Market Cap
$4.56M
Enterprise Value
$3.27M
Total Cash (Recent Filing)
$4.82M
Total Debt (Recent Filing)
$9,452
Price to Earnings (P/E)
―
Beta
3.75
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Reported Leverage

Reported debt is only about $9K against $1.36M of TTM equity, limiting direct interest and leverage pressure in the near term. This gives the company some balance-sheet flexibility while it funds development, although it does not offset severe cash burn.

Expanded Therapeutic Pipeline

Combining with Redx would broaden Skye beyond its current metabolic focus into fibrotic disease, while the proposed Fibrx platform includes a Phase 2 lead asset and broader pipeline. If completed, this could improve program diversification and milestone potential.

Secured External Funding

The proposed financing package would provide substantial capital for clinical development and key milestones through 2029. That funding could reduce near-term financing pressure and support execution of the combined company’s pipeline, although operations remain externally funded.

Bears Say

Pre-Revenue Losses

Zero revenue and large recurring losses show the company has not yet commercialized a product or established an operating earnings base. Losses rose from about $26.6M in 2024 to $55.9M in 2025 and remained elevated TTM, leaving profitability dependent on successful development.

Persistent Cash Burn

Operating and free cash flow remain negative in every period, with TTM burn around $30.6M. Because operations are not self-funding, continued clinical development and corporate activity depend heavily on external capital, making liquidity and financing execution central to the outlook.

Nasdaq Compliance Risk

Negative stockholders’ equity of $497,307 at June 30, 2026 breached Nasdaq’s $2.5M requirement and creates a continuing compliance overhang. Remediation efforts and possible delisting could disrupt exchange access and complicate the Redx transaction and future financing.

Skye Bioscience News

SKYE FAQ

What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $0.50 and its highest was $11.04 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $4.56M.
When is Skye Bioscience’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Nov 05, 2026. The company reported $0.014 earnings per share for the quarter, beating the consensus estimate of -$0.765 by $0.779.
Is Skye Bioscience overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 4,423,469 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of $0.014 in its last earnings report, beating expectations of -$0.765. Following the earnings report the stock price went down -8.772%.
Which hedge fund is a major shareholder of Skye Bioscience?
Hedge funds hold Skye Bioscience shares: the largest hedge-fund position in Skye Bioscience is 72,332,123 shares, and hedge funds decreased their holdings by 6.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology